# Cygenta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cygenta

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.cgtcdmo.com
- Latest round: Series A (Feb 9, 2026)
- Investors on record: 2

## About

Established in 2022 and based in Beijing, China, Beijing Cygenta Biotech Co., Ltd., trading as Cygenta, is a biotechnology service company. The company has a total area of ??more than 8,000 square meters of cGMP facilities. In February 2026, Cygenta raised a series A+ funding from new investors Shennong Capital, Shunxi Fund and Smart Choice Wealth.

The company’s main business is offering end-to-end CDMO solutions for cell and gene therapies, including process development, quality control, and GMP production of plasmids, viral vectors, and cell-based therapeutics. The company’s self-developed platforms cover high-yield plasmid fermentation (5–200 L), scalable viral vector production (3–200 L), and flexible cell therapy manufacturing for both autologous and allogeneic applications. Its products are used in the field of gene and cell therapy drug development.

The company generates revenue by providing fee-for-service CDMO solutions, including process optimization, analytical method development, GMP production of plasmids/viruses/cell products, and regulatory support, complemented by facility leasing and quality control testing for biopharma partners.

## Funding rounds

- Series A, Feb 9, 2026 — Shunxi Fund, Shennong Capital

## Investors

- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series A
- Shennong Capital (https://capitalatlas.ai/funds/shennong-capital) — Series A